Medicus, Vol. 29 No. 2 COVID-19, 2020.
Review article
Treating COVID-19
Marija Santini
Marija Kusulja
Abstract
With the start of 2020, the world faced a pandemic of a new, potentially dangerous infectious disease called COVID-19, and the virus SARS-CoV-2 has been identified as its causative agent. This pandemic has given rise to many questions for clinicians. One of the most significant is the possibility of etiological treatment. From its onset, attempts have been made to repurpose long-known drugs like hydroxychloroquine, chloroquine, and lopinavir/ritonavir, but new drugs such as remdesivir and monoclonal antibodies have also been identified. In addition to etiological treatment, immunomodulatory drugs, such as corticosteroids and tocilizumab, have been recognized as playing an important role. Currently, no drug bears enough evidence of its efficacy and safety to be recommended with a high level of certainty. At present, numerous clinical trials are underway, that are expected to provide answers on the effectiveness and safety of investigational drugs and procedures.
Keywords
COVID-19; SARS-CoV-2; hydroxychloroquine; chloroquine; remdesivir; azithromycin; favipiravir; tocilizumab; convalescent plasma; intravenous immunoglobulins (IVIG)
Hrčak ID:
244325
URI
Publication date:
30.9.2020.
Visits: 4.764 *